Horan Securities Inc. raised its holdings in shares of Johnson & Johnson (NYSE:JNJ – Free Report) by 6.2% in the first quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 4,951 shares of the company’s stock after purchasing an additional 287 shares during the quarter. Johnson & Johnson accounts for 0.4% of Horan Securities Inc.’s portfolio, making the stock its 17th largest position. Horan Securities Inc.’s holdings in Johnson & Johnson were worth $767,000 as of its most recent SEC filing.
Several other hedge funds also recently added to or reduced their stakes in JNJ. Twelve Points Wealth Management LLC lifted its stake in Johnson & Johnson by 27.4% during the first quarter. Twelve Points Wealth Management LLC now owns 11,325 shares of the company’s stock worth $1,755,000 after purchasing an additional 2,439 shares during the last quarter. First Hawaiian Bank grew its position in Johnson & Johnson by 50.3% in the 1st quarter. First Hawaiian Bank now owns 31,526 shares of the company’s stock worth $4,887,000 after purchasing an additional 10,556 shares during the last quarter. M. Kraus & Co raised its stake in Johnson & Johnson by 2.5% during the 1st quarter. M. Kraus & Co now owns 58,182 shares of the company’s stock valued at $9,018,000 after acquiring an additional 1,426 shares in the last quarter. Archford Capital Strategies LLC raised its stake in shares of Johnson & Johnson by 16.6% during the first quarter. Archford Capital Strategies LLC now owns 11,815 shares of the company’s stock valued at $1,957,000 after purchasing an additional 1,686 shares in the last quarter. Finally, First National Bank Sioux Falls raised its position in shares of Johnson & Johnson by 2.2% during the 1st quarter. First National Bank Sioux Falls now owns 5,222 shares of the company’s stock worth $809,000 after buying an additional 111 shares in the last quarter. 67.57% of the stock is owned by institutional investors and hedge funds.
Analyst Upgrades and Downgrades
Several research firms have recently weighed in on JNJ. Citigroup assumed coverage on shares of Johnson & Johnson in a research report on Tuesday, May 30th. They set a “buy” rating and a $185.00 price objective for the company. Morgan Stanley upped their price target on Johnson & Johnson from $179.00 to $183.00 and gave the company an “equal weight” rating in a research report on Wednesday, April 19th. StockNews.com began coverage on shares of Johnson & Johnson in a research note on Thursday, May 18th. They set a “strong-buy” rating for the company. TheStreet cut Johnson & Johnson from a “b” rating to a “c+” rating in a research note on Friday, May 19th. Finally, Raymond James decreased their price objective on shares of Johnson & Johnson from $185.00 to $181.00 and set an “outperform” rating for the company in a report on Wednesday, April 19th. Seven analysts have rated the stock with a hold rating, five have assigned a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $171.57.
Insider Buying and Selling
Johnson & Johnson Trading Down 1.3 %
Shares of JNJ opened at $163.35 on Wednesday. Johnson & Johnson has a 12-month low of $150.11 and a 12-month high of $181.04. The firm has a market capitalization of $424.50 billion, a price-to-earnings ratio of 34.17, a P/E/G ratio of 2.83 and a beta of 0.55. The stock’s 50-day moving average price is $160.74 and its 200 day moving average price is $162.73. The company has a quick ratio of 0.85, a current ratio of 1.07 and a debt-to-equity ratio of 0.49.
Johnson & Johnson (NYSE:JNJ – Free Report) last posted its earnings results on Tuesday, April 18th. The company reported $2.68 earnings per share for the quarter, beating analysts’ consensus estimates of $2.51 by $0.17. The business had revenue of $24.75 billion for the quarter, compared to analysts’ expectations of $23.61 billion. Johnson & Johnson had a net margin of 13.22% and a return on equity of 36.13%. The firm’s revenue for the quarter was up 5.6% on a year-over-year basis. During the same quarter in the previous year, the firm posted $2.67 earnings per share. As a group, research analysts predict that Johnson & Johnson will post 10.66 earnings per share for the current year.
Johnson & Johnson Increases Dividend
The company also recently declared a quarterly dividend, which was paid on Tuesday, June 6th. Shareholders of record on Tuesday, May 23rd were given a $1.19 dividend. The ex-dividend date of this dividend was Monday, May 22nd. This is a positive change from Johnson & Johnson’s previous quarterly dividend of $1.13. This represents a $4.76 dividend on an annualized basis and a yield of 2.91%. Johnson & Johnson’s payout ratio is 99.58%.
Johnson & Johnson Company Profile
Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Consumer Health segment provides skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR. CI:LABO, NEUTROGENA, and OGX brands; baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; TYLENOL acetaminophen products; SUDAFED cold, flu, and allergy products; BENADRYL and ZYRTEC allergy products; MOTRIN IB ibuprofen products; NICORETTE smoking cessation products; and PEPCID acid reflux products.
Read More
- Five stocks we like better than Johnson & Johnson
- Tesla Production Cranks Into High Gear, Shares Follow
- Ford Soars 30% YTD After Breaking Out: What’s Next?
- Acuity Brands Lights Up Opportunity In The Industrial Sector
- Overstock Looks Beyond Overbought After Bed Bath Re-Brand
- Tecnoglass Shines Bright As Analysts Bullish On Growth Potential
Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ – Free Report).
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.
